Samuel Recob, MD
Family Medicine · Laurel, NENPI 1427218577
Payments from drug & device makers
Across 97 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$271
- AbbVie$179
- Lilly USA, LLC$118
- Astellas Pharma US Inc$116
- Novo Nordisk$97
- Novartis$92
- plus $611 from 23 others
What the payments were for
- Food & beverage$1,46599%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 19 | $271 |
| AbbVie(2 entities) | 11 | $179 |
| Lilly USA, LLC | 9 | $118 |
| Astellas Pharma US Inc | 7 | $116 |
| Novo Nordisk | 6 | $97 |
| Novartis | 5 | $92 |
| Pfizer | 5 | $75 |
| Bayer | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 3 | $42 |
| Boehringer Ingelheim | 3 | $40 |
| Radius Health, Inc. | 2 | $38 |
| Merck | 2 | $30 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Electromed, Inc. | 2 | $29 |
| AstraZeneca | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Biogen | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Exact Sciences | 1 | $16 |
| GSK | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
How this compares
$1,485 in reported general payments places this provider in the 65th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 288 | $193,399 |
| TrulicityDulaglutide | 70 | $55,695 |
| OzempicSemaglutide | 48 | $49,738 |
| XifaxanRifaximin | 11 | $39,515 |
| JardianceEmpagliflozin | 47 | $32,620 |
| MyrbetriqMirabegron | 64 | $27,856 |
| MounjaroTirzepatide | 26 | $26,284 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $21,488 |
| FarxigaDapagliflozin Propanediol | 55 | $17,429 |
| XareltoRivaroxaban | 36 | $13,308 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $12,804 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $12,510 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $11,419 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,019 |
| LyricaPregabalin | 12 | $10,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica, Abrysvo, Lipitor | $75 | $215,003332 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $118 | $81,97996 claims |
| Novo NordiskOzempic, Novolog | $97 | $52,49562 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta | $40 | $51,40180 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $116 | $35,03977 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $20 | $33,60591 claims |
| Johnson & JohnsonXarelto | $11 | $13,30836 claims |
| GSKShingrix | $15 | $10,30849 claims |
| BayerKerendia | $63 | $8,11712 claims |
| AbbVieLinzess | $179 | $6,11812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Laurel
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.